The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...

On Wednesday, a jury in Cook County Circuit Court in Illinois ended in a mistrial in a case against Zantac manufacturer ...

The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.

The recent trial regarding the discontinued heartburn drug Zantac, which allegedly causes cancer, ended in a hung jury. The ...

Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...

Boehringer Ingelheim today announced that the FIBRONEER-IPF trial met its primary endpoint, which was the absolute change ...

CDR-Life and Boehringer Ingelheim announced their collaboration and licensing agreement in May 2020, followed by the ...

Boehringer Ingelheim pivotal phase-III FIBRONEER-IPF study of nerandomilast meets primary endpoint: Ingelheim, Germany Tuesday, September 17, 2024, 13:00 Hrs [IST] Boehringer Inge ...

Life, is a highly specific antibody fragment, possibly enabling an optimized penetration through all retinal layers to the ...

The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for Biomedical Artificial Intelligence (AI) based on a € 150 million funding from the ...

Communities that are considered underserved often struggle to attain healthcare services. One of those groups are smallholder ...

This summary presents key updates in the health sector. Highlights include UnitedHealth's tech unit customers adopting ...